Australia Greenlights Chemotherapy-Free Immunotherapy for Relapsed Follicular Lymphoma

Australian adults battling relapsed or refractory follicular lymphoma have just gained access to a groundbreaking, chemotherapy-free treatment. As of August 1, 2026, Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, is officially listed on the Pharmaceutical Benefits Scheme (PBS), making it the country's first and only CD19 and CD20 dual-targeted immunotherapy regimen funded for this difficult-to-treat blood cancer. This milestone offers a crucial new option for patients whose disease has returned or stopped responding to previous therapies. This new listing follows Minjuvi Australian registration by the Therapeutic Goods Administration (TGA) in April 2026, a process expedited through the international 'Project Orbis' initiative. The decision was underpinned by compelling data from the global Phase 3 inMIND clinical trial, which demonstrated a significant 57% reduction in the risk of disease progression, relapse, or death for patients receiving the Minjuvi combination, with a median progression-free survival of 22.4 months compared to 13.9 months in the control group. Follicular lymphoma is the second most common non-Hodgkin lymphoma, affecting over 10,000 Australians and seeing about 1,500 new diagnoses each year, and for many, it remains an incurable condition characterized by repeated relapses. The availability of this chemotherapy-free option marks a significant shift, potentially setting a new standard of care in Australia and offering patients a more tolerable treatment path with improved outcomes. With similar approvals already in place across the US, Europe, and Japan for follicular lymphoma or diffuse large B-cell lymphoma, the global medical community will be watching closely for further real-world data and the potential for this innovative dual-targeted immunotherapy to extend its reach and impact on patient care worldwide.